Company intelligence / Profile preview
Shenzhen 01 Life Technology
Shenzhen, Guangdong, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Shenzhen 01 Life Technology has a diverse early-stage pipeline with 8 preclinical programs and 1 program in Phase 1 clinical trials as of August 2025. Top pipeline candidate AD-101 targets the aryl hydrocarbon receptor (AHR) for atopic dermatitis. Additional programs focus on immune system and metabolic diseases.
- Therapeutic areas
- ImmunologyRare DiseasesDermatology
- Modalities
- Small moleculeLive biotherapeutic product therapyChemical drugRecombinant protein
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Shenzhen 01 Life Technology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shenzhen 01 Life Technology.